About Us | Location | Request Information | Site Map
Home Research Past Clinical Studies

»Current Clinical Studies
»Ongoing Clinical Studies (closed for enrollment)
»Longitudinal Studies
νPast Clinical Studies
  »DNA/RNA/Serum/ Plasma/Urine Banking
  »Computerized ADAS
  »Homocysteine Reduction & Slowing Cognitive Decline
  »Mild Cognitive Impairment Normal Control Study
  »Non-Steroidal Study
  »CATIE (pdf)
  »Prevention Instruments
Click here to print this page     


Phamacogenomics, the use of genetic information to predict drug effects, is an exciting new approach to obtaining optimal results with drug therapy. Drug response and metabolism are largely determined by genetic factors. Knowing which genes are key to complex common illnesses such as schizophrenia, arteriosclerosis, rheumatoid arthritis, depression, Alzheimer's disease, diabetes and others in a given individual will allow doctors to determine which medications are more likely to be effective and less likely to induce side effects.

In this study, DNA/RNA/SERUM/PLASMA/URINE samples from subjects with Alzheimer's disease will be collected and stored for future genetic research involving data linking genes to diseases and treatments.

What is the objective of this study?
The objective of this study is to collect DNA/RNA/SERUM/PLASMA/URINE samples from individuals that have Alzheimer's disease. The samples will be stored for future research. The future research will be used to delineate diagnostic and vlunerability markers for the disease, enhance the understanding of treatment response and side effects, and develop new targets for future drug development.

What does participation in this study involve?
Blood and urine samples will be collected from the patient. Information pertaining to family history will be collected through interview with the caregiver. Subjects with Alzheimer's disease will be evaluated using the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), Clinical Dementia Rating (CDR), and Mini-Mental Status Examination (MMSE).

How will this study be conducted?
This study will involve two visits by the patient. The first visit will consist of informed consent, data collection, rating scales, blood draw, and urine collection. The second visit will consist of a second blood draw and urine collection.This will be the last visit by the patient.

How many patients will be participating in this study?
A total of 500 patients will be recruited for the study with 60 patients from USC.

Who is eligible to participate in this study?
The following are the eligibility criteria for this study:
  • Patients must have diagnosis of probable Alzheimer's disease
  • Must be aged 50-90 years
  • Patients must be of Caucasian (European descent), origin
  • Patients must be currently taking an anti-Alzheimer's medication of the anticholinesterase type

Who is not eligible to participate in this study?
Patients with the following criteria are ineligible for this study:
  • Patients less than 50 years old or greater than 90 years old
  • Evidence of bipolar disorder, Parkinson's disease, drug intoxication, thyroid disease,Huntington's disease, Creutzfeldt-Jakob disease, and Korsakoff's syndrome
  • Sudden
  • Subjects must be currently taking an anti-Alzheimer's medication of the anticholinesterase type

How can I enroll in this study?
This study is currently enrolling volunteers. If interested, please contact:
Randall Sanabria, Margaret Villa, R.N.
University of Southern California Keck School of Medicine
(323) 442-7600

Links: About Us | Maps | Request Information | Site Map | Research | Current Clinical Studies | People | Memory Impairment and Alzheimer's Disease | Resources